We are a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases.
Our mission is to develop innovative, transformative therapies for patients with devastating diseases through novel genome editing. The company’s genome-editing platform, including its Cas12a chRDNA technology, enables superior precision to develop cell therapies that are armored to potentially improve activity against diseases. Caribou is advancing CB-010 and CB-011 as off-the-shelf CAR-T cell therapies that have the potential to provide broad access and rapid treatment for patients with hematologic malignancies.
Caribou Biosciences is a leader in the CRISPR field, successfully leveraging its proprietary genome-editing technologies to develop allogeneic cell therapies that are potentially transformative for patients.
